Jump to content

Lymph node biopsy: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Indications: fixed references...
Line 46: Line 46:
}}
}}
*{{cite book|title=AJCC cancer staging manual|year=2010|publisher=Springer|location=New York|isbn=978-0-387-88440-0|author=American Joint Committee on Cancer|edition=7th ed.|editor=Stephen B. Edge}}
*{{cite book|title=AJCC cancer staging manual|year=2010|publisher=Springer|location=New York|isbn=978-0-387-88440-0|author=American Joint Committee on Cancer|edition=7th ed.|editor=Stephen B. Edge}}
*{{Citation |author=National Comprehensive Cancer Network |year=2012 |title=National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines): melanoma |publisher=National Comprehensive Cancer Network |publication-place=[[Fort Washington, Pennsylvania]] |page= |url=https://subscriptions.nccn.org/gl_login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf |accessdate=5 December 2013}}{{closed access}}</ref> Patients with meleanoma in situ, T1a melanoma or T1b melanoma ≤ 0.5mm have a low risk of cancer spreading to lymph nodes and high 5-year survival rates, so this kind of biopsy is unnecessary.<ref name="AADfive">
*{{Citation |author=National Comprehensive Cancer Network |year=2012 |title=National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines): melanoma |publisher=National Comprehensive Cancer Network |publication-place=[[Fort Washington, Pennsylvania]] |page= |url=https://subscriptions.nccn.org/gl_login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf |accessdate=5 December 2013}}{{closed access}}</ref> Patients with meleanoma in situ, T1a melanoma or T1b melanoma ≤ 0.5mm have a low risk of cancer spreading to lymph nodes and high 5-year survival rates, so this kind of biopsy is unnecessary.<ref name="AADfive"/>


==Procedure==
==Procedure==

Revision as of 18:11, 6 February 2014

Lymph node biopsy
ICD-9-CM40.11
MedlinePlus003933

Lymph node biopsy is a test in which a lymph node or a piece of a lymph node is removed for examination under a microscope (see: biopsy).

The lymphatic system is made up of several lymph nodes connected by lymph vessels. The nodes produce white blood cells (lymphocytes) that fight infections. When an infection is present, the lymph nodes swell, produce more white blood cells, and attempt to trap the organisms that are causing the infection. The lymph nodes also try to trap cancer cells.

Indications

Lymph node biopsies may be performed to evaluate the spread of cancer.

Sentinel lymph node biopsy for evaluating early, thin melanoma has not been shown to improve survival, and for this reason, should not be performed.[1]

  • Bichakjian, C. K.; Halpern, A. C.; Johnson, T. M.; Foote Hood, A.; Grichnik, J. M.; Swetter, S. M.; Tsao, H.; Barbosa, V. H.; Chuang, T. Y.; Duvic, M.; Ho, V. C.; Sober, A. J.; Beutner, K. R.; Bhushan, R.; Smith Begolka, W.; American Academy Of, D. (2011). "Guidelines of care for the management of primary cutaneous melanoma". Journal of the American Academy of Dermatology. 65 (5): 1032–1047. doi:10.1016/j.jaad.2011.04.031. PMID 21868127.
  • American Joint Committee on Cancer (2010). Stephen B. Edge (ed.). AJCC cancer staging manual (7th ed. ed.). New York: Springer. ISBN 978-0-387-88440-0. {{cite book}}: |edition= has extra text (help)
  • National Comprehensive Cancer Network (2012), National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines): melanoma (PDF), Fort Washington, Pennsylvania: National Comprehensive Cancer Network, retrieved 5 December 2013Closed access icon</ref> Patients with meleanoma in situ, T1a melanoma or T1b melanoma ≤ 0.5mm have a low risk of cancer spreading to lymph nodes and high 5-year survival rates, so this kind of biopsy is unnecessary.[1]

Procedure

The test is done in an operating room in a hospital, or at an outpatient surgical facility. There are two ways the sample may be obtained:

Needle biopsy

A needle biopsy involves inserting a needle into a node to obtain the sample.

The patient lies on the examination table; the biopsy site is cleansed; and a local anesthetic is injected. The biopsy needle is then inserted into the node. A sample is removed, pressure is applied to the site to stop the bleeding, and a bandage is applied.

Open biopsy

An open biopsy consists of surgically removing all or part of a node.

The patient lies on the examination table and is given a sedative. The skin over the biopsy site is cleansed, and a local anesthetic is injected (occasionally, a general anesthetic is given). A small incision is made, and the lymph node or part of the node is removed. The incision is then closed with stitches and bandaged.

The sample is then sent to pathology.

With this test there is a small chance of infection or bleeding. Additionally, there is a moderate risk of nerve injury, localized paralysis, or numbness when the biopsy is performed on a lymph node close to nerves.

Test results

The test is used to help determine the cause of lymph node enlargement (swollen glands or lymphadenitis). It may also determine whether tumors in the lymph node are cancerous or noncancerous. Enlarged lymph nodes may be caused by a number of conditions, ranging from very mild infections to serious malignancies. Benign conditions can often be distinguished from cancerous and infectious processes by microscopic examination. The pathologist may also perform additional tests on the lymph node tissue to assist in making a diagnosis.

Some of the conditions where abnormal values are obtained are: